(Reuters) - J.C. Penney Co Inc's decision to shore up its cash reserves by issuing almost $1 billion in new shares sent its stock tumbling more than 13 percent Friday. Earlier in the day, the struggling U.S. department store chain had cut its …
Billionaire financier George Soros seems to be showing faith in J.C. Penney's chances at a turnaround, taking a 7.9% stake in the struggling retailer. The hedge fund titan bought nearly 17.4 million shares through his Soros Fund …
Wall Street doesn't seem to like J.C. Penney's new everyday low pricing any better than Main Street does. The department store chain's stock plunged nearly 20 percent Wednesday -- down $6.57 to close at $26.75. The drop …
NEW YORK – Wall Street doesn’t seem to like J.C. Penney’s new everyday low pricing any better than Main Street does. The department store chain’s stock plunged nearly 20 percent on Wednesday – the biggest decline in at least four …
Nina Garcia and her Twitter account are making moves for JCPenney! Marie Claire's fashion director was recently named the retailer's Style Voice curator, and now she's making JCP's stock soar in less than 140 characters. Nina tweeted: …
J.C. Penney’s stock sale reflects a particular sort of dimness about discounts. The troubled U.S. retailer is struggling to get prices right in its stores and isn’t faring any better in the markets. It is selling over $900 million of shares at $9.65 ...
Wall Street ratings agencies set the tone for today's stock market. Active Network (NYSE:ACTV): Shares, no longer trading on fundamentals following yesterday's buyout bid, are downgraded to Hold from Buy at Jefferies. Its amended …
... WIRE)--Zamansky LLC announces that it has commenced an investigation of J.C. Penney Corporation
A number of leading Wall Street firms also lowered their price targets on the company. J.C. Penney shares closed down $6.57 at $26.75 on the New York Stock Exchange. The decline was the worst percentage decline since the company …
Among the companies with shares expected to trade actively in Wednesday’s session are J.C. Penney Co., Heron Therapeutics Inc., and Intra-Cellular Therapies Inc.